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Purpose: The goal of this study was to compare the risk of developing cancer between patients 
with or without chronic obstructive pulmonary disease (COPD), and to assess the role of gender 
as well as the use of respiratory medication on the risk of developing lung cancer in COPD 
patients.
Patients and methods: We used the UK-based General Practice Research Database to 
conduct a follow-up study with a nested case-control analysis. We identified all patients with a 
first-time COPD diagnosis aged 40–79 years between 1995 and 2005 and a matched COPD-free 
comparison group. We then identified all patients who received an incident cancer diagnosis 
during follow-up.
Results: Among 35,772 COPD patients and 35,772 COPD-free patients, we identified 
4506 patients with an incident cancer diagnosis, of whom 2585 (57.4%) had a previous COPD 
diagnosis, yielding a crude incidence rate ratio of 1.64 (95% CI 1.55–1.74). The increased risk 
was mainly driven by a high lung cancer risk among COPD patients, while other cancers not 
associated with smoking were not statistically significantly associated with an altered COPD 
risk. In the nested case-control analysis, the odds ratio (OR) for lung cancer associated with 
COPD was higher for women (OR 5.26, 95% CI 3.64–7.61) than for men (OR 2.10, 95% CI 
1.70–2.60). In the nested case-control analysis, none of the respiratory drugs were associated 
with a substantially altered risk of developing lung cancer among COPD patients.
Conclusion: Our findings provide further evidence that COPD is associated with an elevated 
lung cancer risk, and that women with COPD may be more susceptible to developing lung cancer 
than men. Overall, respiratory medication did not have an influence on cancer risk.
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Introduction
According to the Global Initiative for Obstructive Lung Diseases (GOLD), chronic 
obstructive pulmonary disease (COPD) is associated with an abnormal inflammatory 
response of the lungs, which is accompanied by a not fully reversible airflow 
limitation.1 The pronounced chronic inflammatory process is thought to increase the 
risk for lung cancer due to constant tissue damage and exposure to substances with 
 mutagenic  potential such as reactive oxygen species.2,3 For other organ systems, similar 
associations between chronic inflammation and cancer have been discussed, such as 
chronic hepatitis and liver cancer.4 Asthma is another major obstructive lung disease 
with substantial inflammation; although studies on the association between asthma and 
lung cancer reported conflicting results, pooled estimates did not provide evidence for 
an association between asthma and an increased cancer risk.5–7





Previous studies on the association between COPD and 
cancer risk mainly focused on lung cancer, suggesting that 
COPD increases the risk for lung cancer materially.8–10 COPD 
patients and lung cancer patients share an important risk 
factor, which is smoking. Men have been reported to have 
higher COPD rates than females, which may be attributed 
to higher smoking rates in males compared with females in 
the past, but smoking rates as well as COPD rates in females 
have been reported to rise.11 In addition, studies indicated 
that female smokers might be more susceptible to developing 
COPD than male smokers, as women with COPD tended to 
suffer from a greater reduction in forced expiratory volume 
in one second (FEV1).12
In vitro and in vivo studies have explored potential 
carcinogenic effects of respiratory drugs, but clinical and 
epidemiological data are scarce. Theophylline and rolipram – a 
more selective phosphodiesterase (PDE) inhibitor – are thought 
to mediate antiapoptotic effects by inhibition of the anti-
 apoptotic Bcl2 protein and by induction of the pro-apoptotic 
Bax protein in cultured H1299 non-small lung carcinoma cells 
(NSCLC) and in B-cells from chronic lymphocytic leukemia 
(CLL) patients.13,14 Positive effects were also seen in CLL 
patients receiving theophylline alone or in combination with 
chlorambucil.15,16 Systemic corticosteroid use, on the other 
hand, has been reported to increase the risk for skin cancer, 
but no such association was seen with inhaled steroids.17 In 
vivo studies, however, suggested anti-proliferative effects 
of glucocorticoids potentially inhibiting the growth of lung 
cancer.18–20 The authors of a recent study reported a reduced 
lung cancer risk in US veterans exposed to high doses of 
inhaled steroids.21 Another study that investigated the role of 
antiasthmatic drug use and cancer risk in asthma patients did 
not find an association between use of inhaled bronchodila-
tors and lung cancer risk, and only a slight increase in risk 
associated with use of oral steroids.22
In this study we explored the association between COPD 
and the risk of developing cancer, and we investigated 
whether the lung cancer risk is associated with use of respi-
ratory drugs among patients with COPD.
Methods
Data source
We used the UK-based General Practice Research Database 
(GPRD) to conduct a follow-up study with a nested case-
control analysis. The GPRD has been described in detail 
elsewhere.23 It is a large primary care database established 
in 1987 that encompasses some five million patients who are 
enrolled with selected general practitioners (GPs) throughout 
the UK. The GPs, who contribute data to the GPRD, have 
been trained to record medical information in a standard 
manner and to supply it anonymously. The recorded informa-
tion includes demographics, medical diagnoses, and virtually 
all drug prescriptions. The patients enrolled in the GPRD are 
representative of the UK population in respect of age, sex, 
and geographical distribution.23 The GPRD has been used 
before for studies of COPD and cancer.22
The GPRD is managed by the Medicines and Healthcare 
products Regulatory Agency (MHRA), and the study protocol 
was approved by the Independent Scientific Advisory Com-
mittee for MHRA database research (ISAC). The investiga-
tors only had access to anonymized information.
Study population
We identified in the GPRD all patients with a first-time 
diagnosis of COPD (based on medical Read or OXMIS 
codes) between January 1, 1995 and December 31, 2005 
at age 40–79 years. We excluded patients with less than 
3 years of active recording history prior to the date of the 
first COPD diagnosis. In addition, we identified at random 
from the GPRD one comparison subject without COPD for 
each COPD patient, matched 1:1 on age (same year of birth), 
sex, general practice, and calendar time (ie, the date of the 
first COPD diagnosis of the COPD patient). We applied 
the same exclusion criteria to the comparison group as to 
the COPD patients.
Follow-up analysis
We excluded all patients from the COPD and the COPD-free 
comparison group with a recorded history of cancer (exclud-
ing non-melanoma skin cancer), HIV, drug abuse, or alcohol-
ism prior to the COPD diagnosis (or the corresponding date 
in the COPD-free group). We then followed all remaining 
patients from the start of follow-up (ie, the COPD diagnosis 
date or the corresponding date in the comparison group) 
and assessed the person-time for each patient until he or she 
developed an incident diagnosis of cancer, left the database, 
died, or reached the end of the study (December 31, 2005), 
whatever came first. We estimated incidence rates with 95% 
confidence intervals (CI) separately for COPD patients and 
COPD-free patients and stratified by age and gender.
nested case-control analysis
We conducted a nested case-control analysis to further 
analyze the impact of COPD, respiratory drugs, and various 
potential confounders on the risk of developing cancer. For 
this purpose we identified for each case with an incident 




cancer risk in patients with cOPD
cancer diagnosis four control patients selected at random 
from the study population (ie, patients with or without COPD 
who did not develop cancer during follow-up). These controls 
were matched to cases on age, sex, practice, and index date 
(ie, the date when the case had the incident cancer diagnosis). 
We compared the prevalence of COPD in patients with cancer 
and controls using conditional logistic regression analyses.
We provided the risk estimates stratified for different can-
cer sites and adjusted for patient characteristics such as body 
mass index (BMI ,18.5, 18.5–25, 25–29.9, 30–60 kg/m2, or 
unknown), smoking history (no, current, past, unknown), as 
well as for various cancer type specific confounders (breast 
cancer: contraceptive use, hormone replacement therapy use, 
benign neoplasms, non-melanoma skin cancer, and NSAID 
use; lymphoma: benign neoplasms, use of carcinogenic 
drugs; gastro-esophageal cancer: gastro-esophageal reflux 
disease, benign neoplasms, non-melanoma skin cancer; 
colorectal cancer: NSAID use, constipation, benign neo-
plasms, non-melanoma skin cancer; female reproductive 
system cancer: contraceptive use, hormone replacement 
therapy use, benign neoplasm, non-melanoma skin cancer, 
NSAID use; urinary system cancers: hypertension, benign 
neoplasms, use of diuretics, use of carcinogenic drugs, 
urinary dysfunction).
Drug exposure
To analyze the association between respiratory medication and 
lung cancer risk we stratified patients into ‘non-users’, ‘cur-
rent users’, or ‘past users’. Current users were patients who 
received their last prescription within 180 days prior to the 
lung cancer diagnosis, and past users were all the patients who 
had prescriptions for the drugs of interest recorded .180 days 
prior to the lung cancer diagnosis. We further subdivided ‘cur-
rent use’ into ‘current short-term use’ of less then a year (ie, 
patients have had their first drug prescription within a year 
prior to the diagnosis), of 1–3 years, or of .3 years. We also 
divided current and past users into ‘regular’ or ‘intermittent’ 
user; in order to be a ‘regular user’, patients had to have at least 
one prescription recorded every 100 days, and if a patient was 
a current user with less than one prescription every 100 days, 
the patient was an ‘intermittent user’.
Statistical analyses were performed with the statistical soft-
ware SAS (release 9.1, SAS Institute, Inc, Cary, NC, USA).
Results
The study population consisted of 35,772 COPD patients and 
the same number of matched COPD-free patients, 51.3% of 
them being male.
Within the study population, we identified a total of 
4506 cancer cases during follow-up, 2585 among the COPD 
patients and 1921 among the COPD-free patients. Sixty-one 
percent of all cancer cases were men (Table 1). The inci-
dence rates (IRs) were 27.8/1000 person-years (py) among 
COPD-patients, and 16.8/1000 py among COPD-free patients 
(Table 2). IRs were higher among men than among women, 
but the incidence rate ratio (IRR) associated with COPD 
was slightly higher in females than in males. The cancer IR 
increased with age.
In the nested case-control analysis we explored the 
association between a history of COPD and the risk of 
developing various types of cancer, stratified by gender 
(Tables 3 and 4). The relative risk was highest for developing 
lung cancer, and it was particularly high in women; OR 5.26 
(95% CI 3.64–7.61), compared with men: OR 2.10 (95% 
CI 1.70–2.60) (likelihood ratio test P , 0.001). The crude 
risk of developing urinary/kidney cancer (in both men and 
women) was also increased, but after adjustment for potential 
confounders the ORs were no longer statistically significantly 
increased. The relative risk of developing one of the other 
cancer types was not or only marginally altered in association 
with a previous COPD diagnosis.
To further analyze the association between COPD 
and lung cancer we did an analysis stratified by smoking 
status. The presence of COPD increased the risk of being 
 diagnosed with lung cancer in non-smokers (OR 4.21, 95% 
CI 2.65–6.69) (Table 5).
Table 1 characteristics of cancer cases and controls 
Cases Controls
COPD COPD-free COPD COPD-free
Age
 40–49 26 19 89 94
 50–59 217 139 706 788
 60–69 743 496 2357 2612
 70–79 1329 992 4343 4775
 80+ 270 275 727 899
Men 1526 1207 5008 5521
Smoking status
 non-smoker 432 896 1915 4673
 current smoker 1049 355 2713 1350
 ex-smoker 926 490 3016 2144
 Unknown 178 180 578 1001
BMi
 15–18.4 126 28 326 87
 18.5–24.9 930 593 2750 2791
 25.0–29.9 699 696 2399 3161
 30.0–60.0 380 282 1332 1470
 Unknown 450 322 1414 1660
Asthma 1266 242 4204 861





In a second sensitivity analysis on the association between 
COPD and lung cancer we assessed respiratory drug use 
in detail among COPD patients (Table 6). The exposure 
prevalence to these drugs was high; short-acting beta agonists 
were used by 70%–80%, short-acting anticholinergic drugs 
by 30%–40%, and inhaled corticosteroids by more than 
50% of COPD patients. For most drugs the proportion of 
lung cancer cases and controls using respiratory drugs on a 
longer-term basis was similar, yielding relative risk estimates 
around one. There was a tendency towards increased relative 
cancer risks associated with short-term current use of most 
respiratory drugs, which can be explained by a worsening 
of COPD symptoms prior to the lung cancer diagnosis. This 
effect was particularly strong for short-term current oxygen 
users with an OR of 5.06 (95% CI 2.87–8.90), and there was 
also a suggestion of an increased lung cancer risk associated 
with current long-term theophylline use (adjusted OR 2.37, 
95% CI 1.05–5.35).
Discussion
In this large population-based study, the overall cancer risk 
was increased in COPD patients as compared with COPD-
free patients. This increased risk was mainly driven by the 
increased lung cancer risk. There was also a suggestion of 
an increased cancer risk for cancers of the urinary and gas-
trointestinal tract, but after adjusting for smoking and other 
covariates the risk estimates no longer reached statistical 
significance. Smoking is the most important risk factor for 
both COPD and lung cancer, and it is likely that most of the 
observed lung cancer risk is due to smoking. However, strati-
fication by smoking status showed that COPD increased the 
risk in non-smokers when comparing non-smoking COPD 
patients with non-smoking patients without COPD, which 
indicates an independent contribution of COPD on the lung 
cancer risk. This proposition is consistent with findings from 
previous studies reporting risk estimates ranging from 1.5 
to 2.7 for various levels of COPD severity.8,9,24 Based on our 
findings from an observational study we cannot tell whether 
the substantially increased OR of 4.21 (95% CI 2.65–6.69) 
for lung cancer among non-smoking COPD patients points 
to a smoking-independent association between COPD and 
lung cancer risk, or whether it is the result of residual con-
founding or smoking misclassification; we cannot rule out 
that the result is driven to some degree by misclassification 
of tobacco exposure, ie, a patient being recorded as a non-
smoker despite a previous history of smoking. Furthermore, a 
COPD diagnosis may be made by mistake because someone 
is presenting with lung cancer symptoms.
Our findings were also similar to the ones in a previ-
ous analysis on lung diseases and cancer risk on the same 
database that covered the period from 1994 to 2001 and 
encompassed only some 9000 subjects with COPD; our study 
was done between 1995 and 2005 and involved some 35,000 
COPD patients.22 Furthermore, we stratified the results of the 
nested case-control analysis by gender, which was not done 
in the previous study.22
Overall, the distribution of various cancer types in the 
current study population reflects what is known from cancer 
Table 2 incidence rate and rate ratio: all cancers by age, gender, and cOPD status




95% CI IRR 95% CI
no cOPD 1921 114441.4 16.8 16.1–17.5 1.00 ref
cOPD 2585 92923.9 27.8 26.8–28.9 1.64 1.55–1.74
Sex
Male   nc 1207 56919.3 21.2 20.1–22.4 1.00 ref
c 1526 45642.3 33.4 31.8–35.1 1.56 1.45–1.68
Female      nc 714 57522.1 12.4 11.5–13.4 1.00 ref
c 1059 47281.7 22.4 21.1–23.8 1.79 1.63–1.96
Age
,50y    nc 19 5133.0 3.7 2.4–5.8 1.00 ref
c 26 4672.2 5.6 3.8–8.1 1.50 0.84–2.69
50–59y      nc 139 19374.0 7.2 6.1–8.5 1.00 ref
c 217 17462.4 12.4 10.9–14.2 1.72 1.40–2.12
60–69y      nc 496 36029.7 13.8 12.6–15.0 1.00 ref
c 743 30570.8 24.3 22.6–26.1 1.75 1.56–1.95
70–79y      nc 992 44520.8 22.3 21.0–23.7 1.00 ref
c 1329 34239.1 38.8 36.8–40.9 1.71 1.58–1.82
 80y   nc 275 9383.9 29.3 26.1–32.9 1.00 ref
c 270 5979.5 45.2 40.2–50.7 1.52 1.28–1.80
Abbreviations: C, COPD; CI, confidence interval; IR, incidence rate; IRR, incidence rate ratio; NC, no COPD; py, person-years; ref, reference category; y, years. 
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Table 3 cancer risk in women
Cases (N = 1007) Controls (N = 4028) OR (95% CI) Adjusted  
OR (95% CI)
gastro-esophageal cancers
 no cOPD 19 93 1.0 1.0
 cOPD 26 87 1.44 (0.75–2.76) 0.92 (0.43–1.98)
intestinal cancers
 no cOPD 51 233 1.0 1.0
 cOPD 63 223 1.28 (0.85–1.91) 1.14 (0.73–1.77)
Lymphoma
 no cOPD 24 89 1.0 1.0
 cOPD 18 79 0.86 (0.45–1.65) 0.86 (0.45–1.65)
Breast cancer
 no cOPD 170 687 1.0 1.0
 cOPD 167 661 1.02 (0.81–1.28) 1.06 (0.82–1.38)
Female genital cancers
 no cOPD 53 184 1.0 1.0
 cOPD 35 168 0.74 (0.47–1.17) 0.82 (0.48–1.37)
Urinary/Kidney cancers
 no cOPD 22 125 1.0 1.0
 cOPD 38 115 1.86 (1.04–3.33) 1.88 (0.83–4.27)
Lung cancer
 no cOPD 41 733 1.0 1.0
 cOPD 280 551 8.35 (5.90–11.8) 5.26 (3.64–7.61)
Notes: OR adjusted for BMI, smoking, and various cancer type specific confounders. Breast cancer: contraceptive use, hormone replacement therapy use, benign neoplasms, 
non-melanoma skin cancer, and NSAID use; lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-esophageal cancer: gastro-esophageal reflux disease, benign 
neoplasms, non-melanoma skin cancer; colorectal cancer: nSAiD use, constipation, benign neoplasms, non-melanoma skin cancer; female reproductive system cancer: 
contraceptive use, hormone replacement therapy use, benign neoplasm, non-melanoma skin cancer, nSAiD use; urinary system cancers: hypertension, benign neoplasms, use 
of diuretics, use of carcinogenic drugs, urinary dysfunction.
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 4 cancer risk in men
Cases (N = 1643) Controls (N = 6572) OR (95% CI) Adjusted  
OR (95% CI)
gastro-esophageal cancers
 no cOPD 63 264 1.0 1.0
 cOPD 58 220 1.09 (0.75–1.60) 1.03 (0.69–1.54)
intestinal cancers
 no cOPD 90 390 1.0 1.0
 cOPD 93 342 1.17 (0.85–1.60) 1.24 (0.88–1.74)
Lymphoma
 no cOPD 34 137 1.0 1.0
 cOPD 38 151 1.01 (0.61–1.68) 1.01 (0.61–1.68)
Male genital cancers
 no cOPD 270 1066 1.0 1.0
 cOPD 231 938 0.97 (0.81–1.18) 1.01 (0.83–1.24)
Urinary/Kidney cancers
 no cOPD 95 444 1.0 1.0
 cOPD 121 420 1.34 (0.99–1.80) 1.08 (0.75–1.57)
Lung cancer
 no cOPD 146 1172 1.0 1.0
 cOPD 404 1028 2.93 (2.40–3.59) 2.10 (1.70–2.60)
Notes: OR adjusted for BMI, smoking, and various cancer type specific confounders. Lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-esophageal cancer: gastro-
esophageal reflux disease, benign neoplasms, non-melanoma skin cancer; colorectal cancer: NSAID use, constipation, benign neoplasms, non-melanoma skin cancer; urinary 
system cancers: hypertension, benign neoplasms, use of diuretics, use of carcinogenic drugs, urinary dysfunction.
Abbreviations: CI, confidence interval; OR, odds ratio.
statistics: in men, lung cancer and cancer of the reproductive 
system (mainly prostate cancer) are the most frequent cancer 
types, followed by colorectal cancer; in women, lung, breast, 
and colorectal cancer are the most common malignancies. 
We observed higher relative lung cancer risk estimates 
associated with a history of COPD for women than for men; 
whether this points towards a greater susceptibility for women, 
or whether it is due to other factors and needs to be further 





explored, is unknown and controversially discussed. Women 
outnumber men in the population of non-smoking COPD 
patients.
We did not find much evidence for an altered lung cancer 
risk in association with long-term use of various respiratory 
drugs. The increased relative risk seen for short-term current 
drug users is most likely due to the fact that respiratory function 
decreased shortly prior to the lung cancer diagnosis, which led 
to the initiation of a new drug treatment. This finding indicates 
that COPD patients with an acute deterioration of their lung 
function need careful evaluation because one of several reasons 
for the worsening clinical situation might be the first manifesta-
tion of lung cancer. There was a suggestion of an increased risk 
of developing lung cancer associated with long-term theophyl-
line use, but this finding was based on a relatively small number 
of exposed cases and controls and may be a chance finding; 
this cannot be ruled out, particularly if a substantial number of 
exposure categories are tested in the model. It may also reflect 
a more advanced and severe stage of COPD and thereby be the 
result of confounding by indication.
Parimon et al reported that high doses of inhaled corti-
costeroids (.1200 mcg/d) reduced the risk of a lung cancer 
diagnosis significantly when compared with non-users.21 
Kiri et al also reported a reduced lung cancer risk in patients 
using inhaled corticosteroids alone or in combination with 
long-acting beta agonists when compared with patients using 
short-acting beta agonists.25 In our study population, we did 
not see a significant association between corticosteroid use 
and the risk of lung cancer. In women with a cancer diagnosis, 
there was a tendency towards a decreased exposure history to 
inhaled corticosteroids as compared with cancer-free controls, 
but the adjusted analysis did not yield a statistically reduced 
risk estimate (data not shown). There was no such effect seen 
in men. In a study involving asthma patients, use of oral corti-
costeroids was associated with an increased cancer risk.22
An important limitation of this study is the limited follow-
up time between the first COPD diagnosis and the incident 
cancer diagnosis. Both COPD and cancer are chronic dis-
eases that develop and are present for some time before first 
symptoms become clinically manifest. Thus, we may have 
missed a certain proportion of patients with mild COPD who 
had not yet been diagnosed by the GP. Further, the proportion 
of patients with severe COPD may be small due to limited 
follow-up. Thus, the current study population may reflect a 
patient population with a relatively high proportion of moder-
ate COPD. In addition, it would have been desirable to have 
more information on certain potential risk factors (eg, human 
papilloma virus infections) or protective factors (eg, former 
use of oral contraceptives (OCs)) for various gynecological 
cancers. We assessed OC use prior to the index date for women 
in the nested case-control analysis and adjusted the analyses 
for this parameter, but for elderly women the likelihood of 
having previous OC use recorded on computer was low. By 
matching cancer cases and controls in practice, we made an 
attempt to take socioeconomic status into account to some 
degree, as social deprivation shows a geographical pattern and 
therefore people from the same neighborhood are more likely 
to see the same GP. We adjusted all our analyses for smoking 
status; however, we cannot exclude residual confounding by 
environmental tobacco exposure or smoking intensity.
A strength of this study is that the GPRD is a well-
validated data source with a high validity of recorded drug 
exposure. In addition, all drug use was recorded prior to these 
analyses and in the absence of any study hypothesis. Further, 
we classified drug use in all patients (ie, cases or controls, 
or patients with or without COPD) in the same way so that 
any exposure misclassification should be non-differentially 
distributed across users of various COPD medications.
In summary, this observational study provides further 
evidence that COPD is only marginally or not at all  associated 
Table 5 Lung cancer risk stratified by smoking status





 non-smoker 32 959 1.00 (ref) 1.00 (ref)
 current smoker 85 281 9.23 (6.00–14.21) 9.04 (5.87–13.94)
 ex-smoker 60 446 3.99 (2.55–6.24) 4.13 (2.63–6.46)
cOPD
 non-smoker 52 339 4.26 (2.69–6.76) 4.21 (2.65–6.69)
 current smoker 337 545 17.19 (11.77–25.09) 16.25 (11.10–23.78)
 ex-smoker 248 581 11.48 (7.81–16.86) 11.62 (7.90–17.09)
Note: OR adjusted for BMi and all variables in the table.
Abbreviations: CI, confidence interval; OR odds ratio; ref, reference category.




cancer risk in patients with cOPD
Table 6 Lung cancer stratified risk by medication use
Cases (%) (N = 684) Controls (%) (N = 1579) Adjusted OR 95% CI
Short-acting beta agonists
no use 161 (23.5) 379 (24.0) ref ref
current ,1y 87 (12.7) 133 (8.4) 1.37 0.94–1.99
current 1–3y 55 (8.0) 112 (7.1) 1.15 0.74–1.77
current .3y 149 (21.8) 365 (23.1) 1.00 0.69–1.43
current few 120 (17.5) 246 (15.6) 1.33 0.95–1.87
Past regularly 68 (9.9) 203 (12.9) 0.90 0.63–1.30
Past few 44 (6.4) 141 (8.9) 0.87 0.56–1.34
Long-acting beta agonists
no use 549 (80.3) 1197 (75.8) ref ref
current ,1y 33 (4.8) 88 (5.6) 0.64 0.41–1.02
current 1–3y 24 (3.5) 63 (4.0) 0.80 0.46–1.40
current .3y 22 (3.2) 61 (3.9) 0.92 0.52–1.65
current few 10 (1.5) 21 (1.3) 1.28 0.55–3.00
Past regularly 39 (5.7) 125 (7.9) 0.69 0.45–1.08
Past few 7 (1.0) 24 (1.5) 0.75 0.28–2.01
Short-acting anticholinergics
no use 450 (65.8) 1084 (68.7) ref ref
current ,1y 76 (11.1) 109 (6.9) 1.33 0.93–1.90
current 1–3y 23 (3.4) 64 (4.1) 0.81 0.46–1.41
current .3y 41 (6.0) 87 (5.5) 1.38 0.87–2.20
current few 18 (2.6) 25 (1.6) 2.00 0.99–4.04
Past regularly 61 (8.9) 176 (11.2) 0.86 0.60–1.23
Past few 15 (2.2) 34 (2.2) 1.35 0.68–2.68
Tiotropium
no use 633 (92.5) 1512 (95.8) ref ref
current ,1y 36 (5.3) 46 (2.9) 1.70 0.98–2.95
current 1–3y 7 (1.0) 15 (1.0) 1.24 0.44–3.49
current .3y – – – –
current few – – – –
Past regularly 8 (1.2) 6 (0.4) 3.31 1.05–10.45
Past few – – – –
Inhaled corticosteroids
no use 309 (45.2) 667 (42.2) ref ref
current ,1y 78 (11.4) 121 (7.7) 1.23 0.85–1.78
current 1–3y 46 (6.7) 11 (7.0) 0.80 0.52–1.25
current .3y 121 (17.7) 341 (21.6) 0.83 0.59–1.17
current few 67 (9.8) 158 (10.0) 0.56 0.59–1.25
Past regularly 45 (6.6) 114 (7.2) 0.91 0.59–1.39
Past few 18 (2.6) 67 (4.2) 0.68 0.37–1.26
Theophylline
no use 611 (89.3) 1434 (90.8) ref ref
current ,1y 7 (1.0) 16 (1.0) 1.29 0.47–3.50
current 1–3y 4 (0.6) 11 (0.7) 0.85 0.23–3.12
current .3y 13 (1.9) 17 (1.1) 2.37 1.05–5.35
current few 2 (0.3) 11 (0.7) 0.57 0.12–2.77
Past regularly 34 (5.0) 63 (4.0) 1.38 0.83–2.29
Past few 13 (1.9) 27 (1.7) 1.47 0.65–3.33
Other xanthines
no use 628 (91.8) 1443 (91.4) ref ref
current ,1y 13 (1.9) 9 (0.6) 5.05 1.86–13.72
current 1–3y 6 (0.9) 8 (0.5) 1.52 0.48–4.82
current .3y 11 (4.6) 29 (1.8) 0.82 0.36–1.86
(Continued)






Cases (%) (N = 684) Controls (%) (N = 1579) Adjusted OR 95% CI
current few 2 (0.3) 3 (0.2) 1.51 0.19–12.18
Past regularly 19 (2.8) 75 (4.8) 0.67 0.38–1.19
Past few 5 (0.7) 12 (0.8) 1.29 0.40–4.13
Oxygen
no use 623 (91.1) 1507 (95.4) ref ref
current ,1y 44 (6.4) 24 (1.5) 5.06 2.87–8.90
current 1–3y 5 (0.7) 9 (0.6) 1.16 0.33–4.09
current .3y 4 (0.6) 7 (0.4) 1.26 0.31–5.16
current few 1 (0.2) 4 (0.3) 0.59 0.06–5.87
Past regularly 6 (0.9) 25 (1.6) 0.56 0.21–1.49
Past few 1 (0.2) 3 (0.2) 1.14 0.10–12.49
Notes: OR adjusted for smoking status, cOPD status, BMi, and all the variables in the table.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference category.
with most cancers except lung cancer. The risk of developing 
lung cancer is substantially increased for COPD patients, 
which can in part be explained by smoking as a major com-
mon underlying risk factor, but an independent association 
between chronic lung inflammation due to COPD and an 
increased cancer risk beyond the effect of smoking is also 
possible. In our study population, the risk of developing 
lung cancer in association with COPD was higher in women 
than in men.
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